Biotech Equity Research: Tracking The Promise (And Risk) Of Early Stage Companies Navigating The Public Markets

October 3, 2024, 3:00 – 4:00 p.m. EST

Benjamin J. Burnett, PhD, Managing Director, Equity Research,
Stifel Investment Services

Register in advance – after registering you will receive Zoom confirmation: https://upstate.zoom.us/meeting/register/tJMoceyqrj4uG9KSdZelOnSJ3toAA4TSwc4P

Ben Burnett, Biotech Equity Research Analyst at Stifel will discuss the intersection of early stage life science companies and finance. We plan to cover recent capital market trends and forecasts, timing the market, and what it takes to become (and be) a public company. Balancing innovation with capital needs requires a good understanding of how and when to access capital, and whether or not this is more easily done as a private or public company. We plan to delve into these concepts in detail and walk through informative case studies of both success and failure.

Benjamin Burnett, PhD, joined Stifel in March of 2018.  Based in Syracuse, NY, Dr. Burnett is a Managing Director, Equity Analyst in the Healthcare sector covering Biotechnology stocks. Dr. Burnett was previously an Associate Vice President working on the team of Paul Matteis covering small-cap and mid-cap biotechnology companies at Stifel. Prior to coming to Stifel, he held a similar role on Mr. Matteis’s team at Leerink focusing primarily on biotechnology stocks. Before starting at Leerink, Dr. Burnett earned a PhD in Biophysics at Cornell University’s medical college (Weill) where he studied the kinetics of protein synthesis and, in particular, the role that G-proteins play in this process.